Actinogen's XanaMIA trial clears latest safety review

By Proactive Investors / August 03, 2026 / www.youtube.com / Article Link


Actinogen Medical's pivotal XanaMIA Alzheimer's disease trial remains on track to report topline results in November 2026.

Recent News

Equity highs and low credit spreads may be warning signs
August 10, 2026 / www.canadianminingreport.com

Gold stocks see strongest week in a decade
August 10, 2026 / www.canadianminingreport.com

Big Gold's strong Q2/26 results continue
August 03, 2026 / www.canadianminingreport.com

Gold stocks see moderate declines

August 03, 2026 / www.canadianminingreport.com

Market still expecting strong growth for major gold producers
July 27, 2026 / www.canadianminingreport.com
See all >
Share to Youtube Share to Facebook Facebook Share to Linkedin Share to Twitter Twitter Share to Tiktok